• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓对损伤的一般反应。

General responses of the bone marrow to injury.

作者信息

Rebar A H

机构信息

School of Veterinary Medicine, Purdue University, West Lafayette, Indiana 47907-1240.

出版信息

Toxicol Pathol. 1993;21(2):118-29. doi: 10.1177/019262339302100202.

DOI:10.1177/019262339302100202
PMID:8210932
Abstract

Hematologic responses in a toxicologic setting may be quite complex and may involve both local as well as systemic manifestations of toxicity and/or pharmacologic responses. Direct toxicity to bone marrow can lead to changes such as marrow necrosis, marrow dysplasia, and macrophage hyperplasia. Some toxic compounds can directly stimulate or suppress the development of 1 or more marrow cell lines. The marrow may also respond to injury at distant sites with increased production of various blood cell elements. Accurate interpretation of hematologic responses generally involves integration of peripheral blood data with bone marrow findings as well as toxicologic findings in other organ systems. This manuscript overviews the various marrow changes encountered in toxicologic studies and provides a perspective of how these changes are best approached from an interpretive viewpoint.

摘要

在毒理学环境中的血液学反应可能相当复杂,可能涉及毒性和/或药理反应的局部及全身表现。对骨髓的直接毒性可导致诸如骨髓坏死、骨髓发育异常和巨噬细胞增生等变化。一些有毒化合物可直接刺激或抑制一种或多种骨髓细胞系的发育。骨髓也可能对远处部位的损伤作出反应,增加各种血细胞成分的生成。血液学反应的准确解释通常需要将外周血数据与骨髓检查结果以及其他器官系统的毒理学检查结果相结合。本文概述了毒理学研究中遇到的各种骨髓变化,并从解释的角度提供了如何最好地处理这些变化的观点。

相似文献

1
General responses of the bone marrow to injury.骨髓对损伤的一般反应。
Toxicol Pathol. 1993;21(2):118-29. doi: 10.1177/019262339302100202.
2
[Clinicopathologic conference. Osteomyelofibrosis/-sclerosis: clinical documentation of a 12-year-long course with sequential biopsies of bone marrow and chromosome analyses].[临床病理讨论会。骨髓纤维化/硬化症:12年病程的临床记录,包括骨髓连续活检及染色体分析]
Med Klin (Munich). 1986 Feb 14;81(3):105-11.
3
Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.真性红细胞增多症研究组关于修订原发性血小板增多症和真性红细胞增多症诊断标准的提议。
Semin Thromb Hemost. 1997;23(4):339-47. doi: 10.1055/s-2007-996107.
4
Circulating hematopoietic progenitor cells in essential thrombocythemia versus prefibrotic/early primary myelofibrosis.
Am J Hematol. 2014 Dec;89(12):1157-8. doi: 10.1002/ajh.23829. Epub 2014 Aug 27.
5
Cellular composition and reticulin fibrosis in chronic myeloid leukaemia.慢性髓性白血病的细胞组成和网状纤维纤维化
Indian J Cancer. 1988 Sep;25(3):128-35.
6
Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components.骨髓纤维化的发病机制:无效巨核细胞生成和巨核细胞成分的作用
Prog Clin Biol Res. 1984;154:427-54.
7
[Bone marrow changes in HIV-positive patients (clinical, cytological, histological, and ultrastructural study of 57 cases)].[HIV阳性患者的骨髓变化(57例患者的临床、细胞学、组织学及超微结构研究)]
Pathologica. 1997 Feb;89(1):36-43.
8
Effect of culture conditions on in vitro erythroid colony formation in myelodysplastic syndromes.培养条件对骨髓增生异常综合征体外红系集落形成的影响。
Exp Hematol. 1990 Nov;18(10):1070-2.
9
Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.异基因骨髓移植后慢性髓性白血病的巨核细胞生成与骨髓纤维化:127例患者的免疫组织化学研究
Mod Pathol. 2001 Feb;14(2):129-38. doi: 10.1038/modpathol.3880269.
10
Osteomyelofibrosis/-sclerosis: a histological and cytogenetic study on core biopsies of the bone marrow.骨髓纤维化/硬化症:一项关于骨髓芯针活检的组织学和细胞遗传学研究
Virchows Arch A Pathol Anat Histol. 1980;389(3):269-86. doi: 10.1007/BF00430655.

引用本文的文献

1
A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm.两例无明确髓系肿瘤的 VEXAS 综合征的临床、组织病理学和分子研究。
Blood Adv. 2022 Jan 25;6(2):405-409. doi: 10.1182/bloodadvances.2021005243.